RxDoctor Payments Data

Nicole Garbe, DO

Family Medicine · St Petersburg, FLNPI 1326427485

Payments from drug & device makers

$1,216in general payments, 2019–2025

Across 56 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$368
  • Novo Nordisk$226
  • Amgen$98
  • AbbVie$94
  • Boehringer Ingelheim$93
  • GSK$83
  • plus $253 from 6 others

What the payments were for

  • Food & beverage$1,216100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,216 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$61,429
Medicare patients
214
Services billed
621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide44$56,877
EliquisApixaban41$49,462
OzempicSemaglutide23$24,704
XareltoRivaroxaban18$23,046
JardianceEmpagliflozin12$15,999
FarxigaDapagliflozin Propanediol16$14,371
Breo ElliptaFluticasone/Vilanterol17$13,112
JanuviaSitagliptin Phosphate13$13,055
VascepaIcosapent Ethyl13$5,255
SynthroidLevothyroxine Sodium42$3,274
BreynaBudesonide/Formoterol Fumarate12$2,500
Atorvastatin Calcium236$1,844
Levothyroxine Sodium217$1,833
Levemir FlexpenInsulin Detemir11$1,797
Oxcarbazepine18$1,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$80$56,87744 claims
Novo NordiskOzempic$226$24,70423 claims
Johnson & JohnsonXarelto$81$23,04618 claims
Boehringer IngelheimJardiance$93$15,99912 claims
AstraZenecaFarxiga$368$14,37116 claims
GSKBreo Ellipta$83$13,11217 claims
MerckJanuvia$28$13,05513 claims
AbbVieSynthroid$94$3,27442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →